Floatz logo

Glembatumumab Vedotin

Recurrent Uveal Melanoma

National Cancer Institute (NCI)antibody_drug_conjugatePhase 2Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
95/ 100

Competitive context

64 Active assets in the Recurrent Uveal Melanoma cohort.

Asset / SponsorPhaseRating
Ifa
Craig L Slingluff, Jr
Phase 2BBB
Tyrosinase Peptide
University of Southern California
Phase 3BB
Cyclophosphamide
Beijing Biotech
Phase 2/3BB
Sargramostim
Thomas Jefferson University
Phase 3BB
Darovasertib
IDEAYA Biosciences
Phase 3BB

View all 50 →

Same molecule, other indications

Glembatumumab Vedotin is also rated in:

triple-negative breast carcinomaDormant
BB
Indicative ·
66 / 100
View asset →
Stage IV Uveal Melanoma AJCC v7Dormant
B
Indicative ·
62 / 100
View asset →
melanomaDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →